Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

By
Charlotte A. Leseman
Alessandro M. Bonomi
Job Schuitema
Stefano Granieri
Margaret Sällberg Chen
Ajay V. Maker
Zeeshan Ateeb
Laura D. Wood
Rogier P. Voermans
Giovanni Marchegiani
Marco Del Chiaro
Johannes C. F. Ket
Anne Marie Lennon
Marc G. Besselink
Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group
June 26, 2026
0 min

1

Intraductal papillary mucinous neoplasm (IPMN) is a precursor to invasive carcinoma and a risk factor for pancreatic ductal adenocarcinoma.
2

Serum CA19.9 levels are used as a tumor marker in pancreatic cancer and may indicate progression to high-grade dysplasia or invasive carcinoma in IPMN.
3

Current guidelines consider CA19.9 levels ≥37 U/mL as a relative indication for surgery, but the role of CA19.9 in IPMN remains controversial.
4

This meta-analysis aims to evaluate the diagnostic accuracy of CA19.9 for identifying high-grade dysplasia and invasive carcinoma in IPMN patients.
5

The study included 24 retrospective studies with 5281 patients, revealing that 20.8% had elevated CA19.9 levels and 41.7% were diagnosed with high-grade dysplasia or invasive carcinoma.

1